Gene therapy costs, manufacturing keeping CBER head 'up at night'

Peter Marks, head of the Food and Drug Administration's Center for Biologics Evaluation and Research, said his top concern for gene therapy's future is manufacturing, and how companies will scale up production to match scientific advances.